<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="7323528 pmid: 3256804519-0846 doi: 10.3201/eid2607.190846 : Synopsis: Synopsis: Transmission of" exact="Chikungunya" post="Virus in an Urban Slum, Brazil Transmission of Chikungunya"/>
 <result pre="of Chikungunya Virus in an Urban Slum, Brazil Transmission of" exact="Chikungunya" post="Virus in an Urban Slum, Brazil Transmission of CHIKV"/>
 <result pre="of Chikungunya Virus in an Urban Slum, Brazil Transmission of" exact="CHIKV" post="in an Urban Slum, Brazil AnjosRosângela O.MugabeVánio AndréMoreiraPatrícia S.S.CarvalhoCaroline"/>
 <result pre="and clinical data by interview and tested serum samples for" exact="CHIKV" post="IgG. CHIKV seroprevalence was 11.8% (95% CI 9.8%–13.7%), and"/>
 <result pre="data by interview and tested serum samples for CHIKV IgG." exact="CHIKV" post="seroprevalence was 11.8% (95% CI 9.8%–13.7%), and 15.3% of"/>
 <result pre="with other arboviral illnesses, such as dengue virus (DENV) and" exact="Zika" post="virus (ZIKV) infections. Noteworthy with chikungunya, the arthralgia is"/>
 <result pre="last for months to years (1,2). After the introduction of" exact="CHIKV" post="into the Caribbean region in 2013, the virus spread"/>
 <result pre="Rico and the US Virgin Islands, the rate at which" exact="CHIKV" post="infection was symptomatic was estimated at &amp;gt;70% (5,6). However,"/>
 <result pre="levels of herd immunity to preclude subsequent epidemics. Furthermore, 2" exact="CHIKV" post="strains were introduced and are cocirculating in the Americas;"/>
 <result pre="the basis of strain type, population, or region. In Brazil," exact="CHIKV" post="was first detected in September 2014, almost simultaneously in"/>
 <result pre="recorded (10). The northeast region was the most affected by" exact="CHIKV" post="(9,10,11); this same area was also the most affected"/>
 <result pre="(9,10,11); this same area was also the most affected by" exact="ZIKV" post="in 2015–2016 (12,13). In Salvador (population 2.9 million [14]),"/>
 <result pre="≈100 km from Feira de Santana, we retrospectively identified that" exact="CHIKV" post="had been circulating since September 2014 (15), but outbreaks"/>
 <result pre="2015 (12,15). In this study, we used the prevalence of" exact="CHIKV" post="IgG as an indicator of all (i.e., symptomatic and"/>
 <result pre="symptomatic. In addition, we investigated factors potentially associated with prior" exact="CHIKV" post="infection. Methods Study Site and Participant Selection We performed"/>
 <result pre="data on prior presumptive clinical diagnosis of DENV, ZIKV, and" exact="CHIKV" post="infection and on history of fever, arthralgia, myalgia, rash,"/>
 <result pre="from the period immediately before and after the peak of" exact="CHIKV" post="transmission in Salvador, which occurred during June–November 2015 (12,15)."/>
 <result pre="using the IgG ELISA technique (Euroimmun, https://www.euroimmun.com) to detect specific" exact="CHIKV" post="IgG. For samples showing positive results for IgG, we"/>
 <result pre="showing positive results for IgG, we then tested with a" exact="CHIKV" post="IgM ELISA (InBios, https://inbios.com); we used the presence of"/>
 <result pre="presence of IgM as a proxy for a more recent" exact="CHIKV" post="infection than if there were no IgM. We interpreted"/>
 <result pre="than if there were no IgM. We interpreted both the" exact="CHIKV" post="IgG and IgM ELISA results according to manufacturer instructions:"/>
 <result pre="CHIKV IgG and IgM ELISA results according to manufacturer instructions:" exact="CHIKV" post="IgG absorbance/calibrator levels were negative at &amp;lt;0.8, indeterminate at"/>
 <result pre="&amp;lt;0.8, indeterminate at ≥0.8 to &amp;lt;1.1, and positive at ≥1.1;" exact="CHIKV" post="IgM absorbance/calibrator levels were negative at &amp;lt;0.9, indeterminate at"/>
 <result pre="60 serum samples (30 positive and 30 negative from the" exact="CHIKV" post="IgG ELISA) for CHIKV to determine ≥90% reductions in"/>
 <result pre="positive and 30 negative from the CHIKV IgG ELISA) for" exact="CHIKV" post="to determine ≥90% reductions in plaque counts (PRNT90), as"/>
 <result pre="to define statistically significant differences. We calculated the prevalence of" exact="CHIKV" post="IgG overall and according to participants’ characteristics and categorized"/>
 <result pre="participants’ characteristics and categorized continuous variables so we could estimate" exact="CHIKV" post="seroprevalence by groups. We stratified age into ranges of"/>
 <result pre="and adjustment for design effect to verify associations between previous" exact="CHIKV" post="infection and the sociodemographic and clinical characteristics of participants."/>
 <result pre="model included only sociodemographic variables to investigate their role in" exact="CHIKV" post="infection, whereas the second model included only clinical characteristics"/>
 <result pre="a positive serologic result. Among the participants with a positive" exact="CHIKV" post="IgG ELISA, we estimated the frequencies of symptomatic CHIKV"/>
 <result pre="positive CHIKV IgG ELISA, we estimated the frequencies of symptomatic" exact="CHIKV" post="infection by calculating the proportion of those who reported"/>
 <result pre="fever simultaneously accompanied by arthralgia after January 2015, likely recent" exact="CHIKV" post="infection by calculating the proportion of those with a"/>
 <result pre="to compare sociodemographic and clinical characteristics between participants with symptomatic" exact="CHIKV" post="infections and those with asymptomatic infections and between participants"/>
 <result pre="between participants with likely recent and those with likely nonrecent" exact="CHIKV" post="infections. We set a two-tailed p value &amp;lt;0.05 to"/>
 <result pre="school education (59.0%) or were illiterate (4.3%). Prevalence of Previous" exact="CHIKV" post="Infection and Associated Factors Among the 1,772 (99.8%) participants"/>
 <result pre="sample, 209 (11.8%, 95% CI 9.8%–13.7%) had had a previous" exact="CHIKV" post="infection, as determined by the detection of CHIKV IgG."/>
 <result pre="a previous CHIKV infection, as determined by the detection of" exact="CHIKV" post="IgG. Of the 30 random IgG ELISA positive samples"/>
 <result pre="Of the 30 random IgG ELISA positive samples tested by" exact="CHIKV" post="PRNT90, 27 (90%) were positive; of the 30 random"/>
 <result pre="(median 3.53, IQR 3.11–3.82). In bivariate analyses, prevalence of previous" exact="CHIKV" post="infection did not differ by sex, skin color, poverty"/>
 <result pre="reported not working (Table 1). Furthermore, the prevalence of previous" exact="CHIKV" post="infection was statistically greater for participants who had received"/>
 <result pre="infection—fever with arthralgia, myalgia, rash, or pruritus—after January 2015, when" exact="CHIKV" post="emerged in Salvador (Table 1). Table 1 Prevalence of"/>
 <result pre="46 (22.3) &amp;lt;0.01 No 1,563 163 (10.4) Presumptive clinical diagnosis" exact="Chikungunya" post="Yes 48 24 (50.0) &amp;lt;0.01 No 1,724 185 (10.7)"/>
 <result pre="Chikungunya Yes 48 24 (50.0) &amp;lt;0.01 No 1,724 185 (10.7)" exact="Dengue" post="Yes 111 21 (18.9) 0.02 No 1,661 188 (11.3)"/>
 <result pre="Dengue Yes 111 21 (18.9) 0.02 No 1,661 188 (11.3)" exact="Zika" post="Yes 147 38 (25.9) &amp;lt;0.01 No 1,625 171 (10.5)"/>
 <result pre="after January 2015. The only sociodemographic characteristic associated with previous" exact="CHIKV" post="infection in the multiple variable analyses was residence on"/>
 <result pre="1.07–2.15) (Table 2). In addition, independent clinical predictors for previous" exact="CHIKV" post="infection included recall of a presumptive medical diagnosis of"/>
 <result pre="(1.23–2.50) Rash 2.28 (1.68–3.08) Pruritus 2.14 (1.51–3.03) Presumptive clinical diagnosis" exact="Chikungunya" post="4.66 (3.35–6.48) 2.83 (1.97–4.05) Dengue 1.67 (1.09–2.56) Zika 2.45"/>
 <result pre="2.14 (1.51–3.03) Presumptive clinical diagnosis Chikungunya 4.66 (3.35–6.48) 2.83 (1.97–4.05)" exact="Dengue" post="1.67 (1.09–2.56) Zika 2.45 (1.78–3.39) *Crude prevalence ratios shown"/>
 <result pre="clinical diagnosis Chikungunya 4.66 (3.35–6.48) 2.83 (1.97–4.05) Dengue 1.67 (1.09–2.56)" exact="Zika" post="2.45 (1.78–3.39) *Crude prevalence ratios shown for variables with"/>
 <result pre="included only sociodemographic variables to investigate potential exposures associated with" exact="CHIKV" post="infection; the second model included only clinical characteristics to"/>
 <result pre="after January 2015. Frequency of Symptomatic Infections among Participants with" exact="CHIKV" post="IgG Of the 209 participants with detected CHIKV IgG,"/>
 <result pre="Participants with CHIKV IgG Of the 209 participants with detected" exact="CHIKV" post="IgG, 32 (15.3%) recalled an episode of fever and"/>
 <result pre="= 0.07); more frequently reported other clinical manifestations compatible with" exact="CHIKV" post="infection, such as myalgia, rash, and pruritus (p&amp;lt;0.01 for"/>
 <result pre="more commonly received a presumptive clinical diagnosis of chikungunya or" exact="Zika" post="(p&amp;lt;0.01 for both) but not of dengue (p ="/>
 <result pre="(14.1) &amp;lt;0.01 No 11 (34.4) 152 (85.9) Presumptive clinical diagnosis" exact="Chikungunya" post="Yes 20 (62.5) 12 (6.8) &amp;lt;0.01 No 12 (37.5)"/>
 <result pre="20 (62.5) 12 (6.8) &amp;lt;0.01 No 12 (37.5) 165 (93.2)" exact="Dengue" post="Yes 4 (12.5) 17 (9.6) 0.62 No 28 (87.5)"/>
 <result pre="4 (12.5) 17 (9.6) 0.62 No 28 (87.5) 160 (90.4)" exact="Zika" post="Yes 18 (56.3) 20 (11.3) &amp;lt;0.01 No 14 (43.7)"/>
 <result pre="January 2015. ‡Data not available for 1 participant with an asymptomatic" exact="CHIKV" post="infection. Frequency of Presumptive Clinical Diagnosis of Chikungunya Among"/>
 <result pre="an asymptomatic CHIKV infection. Frequency of Presumptive Clinical Diagnosis of" exact="Chikungunya" post="Among the 209 participants with a previous CHIKV infection,"/>
 <result pre="Diagnosis of Chikungunya Among the 209 participants with a previous" exact="CHIKV" post="infection, 24 (11.5%) reported receiving a clinical presumptive diagnosis"/>
 <result pre="1.5% (24/1,563) frequency among the participants who were negative for" exact="CHIKV" post="IgG (p&amp;lt;0.01). Noteworthy for the 32 CHIKV-infected participants who"/>
 <result pre="having received a clinical presumptive diagnosis of chikungunya, 24 had" exact="CHIKV" post="IgG detected, indicating a positive predictive value of 50%"/>
 <result pre="predictive value of 50% for the presumptive diagnosis. Frequency of" exact="CHIKV" post="IgM Among the 209 participants who were positive for"/>
 <result pre="CHIKV IgM Among the 209 participants who were positive for" exact="CHIKV" post="IgG, 49 (23.4%) also had CHIKV IgM, possibly indicating"/>
 <result pre="who were positive for CHIKV IgG, 49 (23.4%) also had" exact="CHIKV" post="IgM, possibly indicating a recent infection. We found no"/>
 <result pre="associations between sociodemographic or clinical characteristics and the presence of" exact="CHIKV" post="IgM (data not shown). Discussion Despite retrospective evidence of"/>
 <result pre="seroprevalence is much lower than that found in 3 additional" exact="CHIKV" post="serologic surveys performed in Brazil at that time. During"/>
 <result pre="de Santana, ≈100 km from Salvador, the prevalence of prior" exact="CHIKV" post="infection was estimated at 57.1%; in the urban area"/>
 <result pre="rural area of Riachão do Jacuípe, the prevalence of prior" exact="CHIKV" post="infection was 20.0% in April 2016 (30). It is"/>
 <result pre="in adjacent cities most possibly indicates that the intensity of" exact="CHIKV" post="transmission, after its first introduction, may vary greatly even"/>
 <result pre="diversity, variations in local geographic and climate conditions, the predominant" exact="CHIKV" post="strain circulating, and even by interactions when the vector"/>
 <result pre="by interactions when the vector species may be coinfected with" exact="CHIKV" post="and other circulating arboviruses, such as ZIKV and DENV."/>
 <result pre="be coinfected with CHIKV and other circulating arboviruses, such as" exact="ZIKV" post="and DENV. Furthermore, a very localized and self-restricted CHIKV"/>
 <result pre="as ZIKV and DENV. Furthermore, a very localized and self-restricted" exact="CHIKV" post="outbreak has been recently described in Salvador (32), which"/>
 <result pre="in specific regions may be responsible for the emergence of" exact="CHIKV" post="and the extent of its spread. In bivariate analyses,"/>
 <result pre="streets where the houses were located were associated with previous" exact="CHIKV" post="infection, pointing to a social gradient that poses an"/>
 <result pre="associated with increased chikungunya incidence. The widely accepted understanding of" exact="CHIKV" post="infection has been that the majority (&amp;gt;70%) of infected"/>
 <result pre="15.3%. Other studies have also found low proportions of symptomatic" exact="CHIKV" post="infection. In Brazil, serologic surveys estimated the proportion of"/>
 <result pre="infection. In Brazil, serologic surveys estimated the proportion of symptomatic" exact="CHIKV" post="infection to be 32.7% in Feira de Santana and"/>
 <result pre="a cohort follow-up in the Philippines, the subclinical incidence of" exact="CHIKV" post="infection was 10.0 per 100 person-years, while the incidence"/>
 <result pre="was 10.0 per 100 person-years, while the incidence of symptomatic" exact="CHIKV" post="infection was 2.2 per 100 person-years, indicating that &amp;lt;20%"/>
 <result pre="symptomatic infection rates may be related to the lineage of" exact="CHIKV" post="that is circulating (39,40), the diversity in human immunological"/>
 <result pre="driven by specific genetic characteristics (41), or even by the" exact="CHIKV" post="exposure dose delivered by mosquitoes (42). In our study,"/>
 <result pre="≥15 years of age were more likely to have symptomatic" exact="CHIKV" post="infections than others, but the power of our analyses"/>
 <result pre="of our analyses was limited by the small number of" exact="CHIKV" post="infections that we detected. However, our results are in"/>
 <result pre="infection becomes symptomatic. We also found that chronic arthralgia after" exact="CHIKV" post="infection was uncommon; the maximum reported duration for the"/>
 <result pre="the disease becoming chronic may occur under certain circumstances of" exact="CHIKV" post="infection. If further investigation supports this hypothesis, this finding"/>
 <result pre="partially explain the low proportion of participants testing positive for" exact="CHIKV" post="who received a correct presumptive diagnosis. We did find"/>
 <result pre="clinical diagnosis of chikungunya disease was strongly associated with having" exact="CHIKV" post="IgG (positive predictive value of 50%). Thus, during and"/>
 <result pre="thus, could not capture potential variations in prior exposure to" exact="CHIKV" post="within the city. However, because the community where we"/>
 <result pre="greater risk of arboviral transmission, it is unlikely that the" exact="CHIKV" post="seroprevalence of the city population overall was much higher"/>
 <result pre="the Pau da Lima community. Second, we used a commercial" exact="CHIKV" post="IgG ELISA to detect previous CHIKV infections. Prior studies"/>
 <result pre="we used a commercial CHIKV IgG ELISA to detect previous" exact="CHIKV" post="infections. Prior studies have reported high accuracy levels for"/>
 <result pre="and the PRNT90. However, because cryoglobulinemia had been described for" exact="CHIKV" post="(45), further surveys should consider this possible effect. Third,"/>
 <result pre="might not occur or may occur at later stages after" exact="CHIKV" post="infection, possibly due to a strong and longlasting CHIKV"/>
 <result pre="after CHIKV infection, possibly due to a strong and longlasting" exact="CHIKV" post="IgM immune response (46). It is possible that this"/>
 <result pre="that this diagnostic limitation hampered detection of some cases of" exact="CHIKV" post="infection, especially those occurring shortly before the survey was"/>
 <result pre="the temporal relation between exposures to risk and occurrence of" exact="CHIKV" post="infection. In summary, our findings suggest that although CHIKV"/>
 <result pre="of CHIKV infection. In summary, our findings suggest that although" exact="CHIKV" post="and ZIKV both spread through Salvador in the same"/>
 <result pre="infection. In summary, our findings suggest that although CHIKV and" exact="ZIKV" post="both spread through Salvador in the same year, 2015"/>
 <result pre="through Salvador in the same year, 2015 (12,15,47), transmission of" exact="CHIKV" post="seems to have been much less intense, reaching ≈12%"/>
 <result pre="≈12% of the population, compared to estimates of 63%–73% for" exact="ZIKV" post="(22,48). Viral competition within hosts and vectors may be"/>
 <result pre="of Brazil and the Americas may be largely susceptible to" exact="CHIKV" post="transmission. It is thus necessary to maintain surveillance to"/>
 <result pre="for vector control, that will help protect the population from" exact="CHIKV" post="and other arboviral infections. Appendix Survey used to collect"/>
 <result pre="infectious diseases of global relevance. References References 1. WeaverSC, LecuitM." exact="Chikungunya" post="virus and the global spread of a mosquito-borne disease.N"/>
 <result pre="et al.; collab: Centers for Disease Control and Prevention (CDC)." exact="Chikungunya" post="cases identified through passive surveillance and household investigations—Puerto Rico,"/>
 <result pre="KraemerMU, de OliveiraLF, et al.Emergence and potential for spread of" exact="Chikungunya" post="virus in Brazil.BMC Med. 2015;13:102. 10.1186/s12916-015-0348-x25976325 8. TeixeiraMG, AndradeAMS,"/>
 <result pre="of cases of dengue, chikungunya fever and fever by the" exact="Zika" post="virus until epidemiological week 49, 2016 [in Portuguese]. Vol."/>
 <result pre="of cases of dengue, chikungunya fever and fever by the" exact="Zika" post="virus until epidemiological week 35, 2017 [In Portuguese]. Vol."/>
 <result pre="of cases of dengue, chikungunya fever and fever by the" exact="Zika" post="virus until epidemiological week 43, 2018 [in Portuguese]. Vol."/>
 <result pre="TauroLB, SilvaMMO, et al.Unrecognized emergence of chikungunya virus during a" exact="Zika" post="virus outbreak in Salvador, Brazil.PLoS Negl Trop Dis. 2017;11:e0005334."/>
 <result pre="AnjosRO, SantosVC, GonçalvesTSF, et al.Concomitant transmission of dengue, chikungunya and" exact="Zika" post="viruses in Brazil: clinical and epidemiological findings from surveillance"/>
 <result pre="NeryN, CastanhaPMS, SacramentoGA, et al.Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region.Science. 2019;363:607–10. 10.1126/science.aav661830733412"/>
 <result pre="CardosoCW, SouzaRL, NascimentoLC, SantosDRD, CamposGS, et al.A localized outbreak of" exact="Chikungunya" post="virus in Salvador, Bahia, Brazil.Mem Inst Oswaldo Cruz. 2019;114:e180597."/>
 <result pre="context and sub-neighborhood scale detail to explain dengue, chikungunya and" exact="Zika" post="patterns in Cali, Colombia.PLoS One. 2017;12:e0181208. 10.1371/journal.pone.018120828767730 38. YoonI-K,"/>
 <result pre="GrandadamM, MarimoutouC, RogierC, Botelho-NeversE, TolouH, et al.Persisting mixed cryoglobulinemia in" exact="Chikungunya" post="infection.PLoS Negl Trop Dis. 2009;3:e374. 10.1371/journal.pntd.000037419190731 46. BozzaFA, Moreira-SotoA,"/>
 <result pre="FischerC, NascimentoAD, CalheirosAS, et al.Differential shedding and antibody kinetics of" exact="Zika" post="and chikungunya viruses, Brazil.Emerg Infect Dis. 2019;25:311–5. 10.3201/eid2502.18016630666934 47."/>
 <result pre="10.3201/eid2112.15116726584464 48. NettoEM, Moreira-SotoA, PedrosoC, HöserC, FunkS, KucharskiAJ, et al.High" exact="Zika" post="virus seroprevalence in Salvador, Northeastern Brazil limits the potential"/>
</results>
